Kindai University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Osaka Japan (1925)

Organization Overview

First Clinical Trial
1993
NCT00147147
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Department of Medical Oncology, Kinki University, Faculty of Medicine | Department of Urology, Kindai University Faculty of Medicine | Hokuriku-Kinki Immunochemotherapy Study Group | Kindai University | Kindai University Faculty of Medicine, Gastroenterology and Hepatology | Kinki-Chuo Chest Medical Center | Kinki University | Kinki University Faculty of Medicine, Department of Gastroenterology and Hepatology | Kinki University Hospital | Kinki University Hospital, Faculty of Medicine, Osaka, Japan | Kinki University School of Medicine | Sakai hospital Kinki University School of Medicine | Sakai Municipal Hospital

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 1)

Carcinoma (Phase 3)

Carcinoma, Hepatocellular (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Esophageal Neoplasms (Phase 1)

Hypersensitivity (Phase 4)

Liver Neoplasms (Phase 3)

Lung Neoplasms (Phase 3)

Lupus Nephritis (Phase 2)

Neoplasms (Phase 3)

Nephritis (Phase 2)

Prostatic Neoplasms (Phase 4)

Small Cell Lung Carcinoma (Phase 2)

Stomach Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 15
  • # of Trial APIs: 23